0001140361-18-021345.txt : 20180502
0001140361-18-021345.hdr.sgml : 20180502
20180502182628
ACCESSION NUMBER: 0001140361-18-021345
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180501
FILED AS OF DATE: 20180502
DATE AS OF CHANGE: 20180502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RAY DEBANJAN
CENTRAL INDEX KEY: 0001706863
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 18801150
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD, SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2018-05-01
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001706863
RAY DEBANJAN
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., SUITE 400
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Financial Officer
Common Stock
2018-05-01
4
M
0
3000
1.2599
A
7741
D
Common Stock
2018-05-01
4
S
0
3000
26.5207
D
4741
D
Stock Option (Right to Buy)
1.2599
2018-05-01
4
M
0
3000
0.00
D
2023-12-10
Common Stock
3000
8710
D
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades in prices ranging from $26.22 to $26.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
100% of the shares subject to the option are fully vested and exercisable.
/s/ Debanjan Ray
2018-05-03